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Dear Editor,
We report a patient with severe anemia due to hereditary
hemorrhagic telangiectasia (HHT) in whom treatment with
anti-VEGF showed a substantial effect [1, 2].
A 44-year-old patient with known HHT type 1 disease
suffered from severe gastrointestinal hemorrhages, pulmo-
nary arteriovenous malformation (AVM), liver AVM, and
severe epistaxis. The patient was treated at the center of
excellence for HHT at Oslo University Hospital and at
Akershus University Hospital, Norway. First spontaneous
epistaxis occurred at the age of 20 years. He was carrying
the endoglin splice mutation c.817-1G>T in exon 6. This
mutation has not been described in the literature until now.
He had a pulmonary AVM, which was embolized when he
was 32 years old. The bleedings from the gastrointestinal
tract were treated by argon plasma coagulation using
combined laparotomy and enteroscopy of the small intes-
tine in June 2003. Later, the gastrointestinal tract was
treated by double balloon enteroscopy and altogether ten
telangiectasies in the ventricle and 120 lesions in the small
intestine were coagulated in February 2009. The telangiec-
tasies in the nasal mucosa were of Mahoney grade 2–3 and
were treated first with pulsed dye laser in 2003, once with
super selective embolization in 2006 and later with argon
plasma coagulation under general anesthesia approximately
three times per year with some effect [3]. Since 2003, he
was transfused regularly and received between 4 and 6 U of
packed red blood cells every week. His regular medication
was tranexamic acid of 1,000 mg twice daily and
intravenous iron once per week. He was started on
thalidomide 50 mg per day in April 2007. The thalidomide
dose was increased gradually to 200 mg per day, and he had
some subjective effect; however, he remained dependent on
regular packed red cell transfusions as before. After 1 year
on thalidomide, he developed peripheral neuropathy, and
the medication was first reduced to 150 mg per day and
finally stopped in January 2009. From October until
December 2009, treatment with 5 mg/kg of bevacizumab
every second week was given without complications. After
the first infusion, he only needed one further unit of packed
red cells and the hemoglobin level remained stable around
10 g/dl without further transfusions. The intravenous iron
infusions were reduced too. He remained stable for 6 weeks
after completion of the first course with bevacizumab
(Fig. 1). He became transfusion dependent again, and a
second course with 5 mg/kg of bevacizumab was initiated
in March 2010. The second course was planned with 5 mg/
kg of bevacizumab every third week. Due to unforeseen
circumstances, there was an interval delay of 5 weeks
between dose 3 and dose 4 during the second course. The
second course initially did show a remarkable effect with a
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DOI 10.1007/s00277-010-1063-5raise in Hb from 7.3 to 10 g/l. The effect was reduced after
the 5 week interval.
Discussion
For the treatment of epistaxis in patients with HHT, several
therapeutic drugs have been recommended. Tranexamic
acid has shown to have some effect; low-dose estrogen–
progesterone showed efficacy in an uncontrolled study, and
oral tamoxifen was shown to be effective in a randomized
placebo-controlled study [4, 5]. From a case report,
bevacizumab had a profound effect on a patient with non-
bleeding vascular AVMs [6].
Conclusion
Bevacizumab was effective in this patient with anemia due
to severe HHT, also when given in intervals of 3 weeks. In
cases with severe visceral AVMs and/or severe intractable
and transfusion-dependent epistaxis due to HHT, we
recommend a 4.5-month treatment regime with 5 mg/kg
of bevacizumab, given in 3-week intervals.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
References
1. Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in
hereditary hemorrhagic telangiectasia after treatment with the vascular
endothelial growth factor (VEGF) antagonist bevacizumab. Ann
Hematol 85(9):631–632
2. Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary
hemorrhagic telangiectasia. N Engl J Med 360(20):2143–2144
3. Mahoney EJ, Shapshay SM (2006) New classification of nasal
vasculature patterns in hereditary hemorrhagic telangiectasia. Am J
Rhinol 20(1):87–90
4. Jameson JJ, Cave DR (2004) Hormonal and antihormonal therapy
for epistaxis in hereditary hemorrhagic telangiectasia. Laryngo-
scope 114(4):705–709
5. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M (2009)
Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a
double-blind placebo-controlled clinical trial. Laryngoscope 119
(2):284–288
6. Mitchell A, Adams LA, Macquillan G, Tibballs J, vanden
Driesen R, Delriviere L (2008) Bevacizumab reverses need for
liver transplantation in hereditary hemorrhagic telangiectasia.
Liver Transpl 14(2):210–213
4,0
5,0
6,0
7,0
8,0
9,0
10,0
11,0
12,0
13,0
14,0
june 04
december 04
june 05
december 05
june 06
december 06
june 07
december 07
june 08
december 08
march 09
june 09
september 09
october 09
october 09
november 09
november 09
december 09
december 09
december 09
january 10
january 10
january 10
march 10
march 10
april 10
april 10
may 10
may 10
june 10
june 10
june 10
june 10
H
b
1
0
2
3
4
5
6
7
P
R
C
Fig. 1 Filled triangles indicate
treatment with bevacizumab.
The bars indicate treatment with
thalidomide. The white line
indicates packed red cells (PRC)
transfused [units per week]
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